Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.02.2013 | short review | Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013

Selected breast cancer highlights from the ASCO 2012

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 1/2013
Autoren:
Univ. Prof. Dr. Edgar Petru, Univ. Ass. Dr. Eva-Christine Weiss

Abstract

The abstracts are a selection of clinically relevant papers presented at the American Society of Clinical Oncology (ASCO) 2012. The results of the EMILIA study were a milestone presented at the meeting. A total of 991 patients with metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer had been pretreated with a taxane and trastuzumab. They were randomized into two groups: Trastuzumab emtansine conjugate (T-DM1) or capecitabine-lapatinib. Significant differences were found with regard to progression-free survival and the two-year overall survival. Another study analyzed the relevance of the hormone-receptor (HR) status for the prognosis of patients with operable HER2-overexpressing breast cancer. A significant difference in the risk of the development of brain metastases was found depending on the HR status. In the MA.27 study, patients received adjuvant therapy with aromatase inhibitors. A significant proportion of cases reported therapy of osteoporosis, mainly with bisphosphonates. Osteoporosis therapy influenced recurrence-free survival. In another study, the prognostic influence of Ki-67 was evaluated before and after neoadjuvant chemotherapy with TAC (docetaxel/doxorubicin/cyclophosphamide). A metaanalysis analyzed the possible discordance between the HR status and the HER2 status in the primary tumor as compared to metastasis in 2,806 breast cancer patients. The estrogen-receptor (ER)-, and the progesterone-receptor (PR) status as well as the HER2 status changed in a significant proportion of cases. Parenteral nutrition in 129 terminal oncological patients with progressive cancer was investigated within a randomized placebo-controlled trial. They either received one liter of 0.9 % physiological saline subcutaneously or placebo. Survival, symptoms of dehydration, and quality of life were analyzed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013 Zur Ausgabe